GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Payments of Debt

Genscript Biotech (HKSE:01548) Payments of Debt : HK$-456 Mil (TTM As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Payments of Debt?

Genscript Biotech's Payments of Debt for the six months ended in Jun. 2024 was HK$-337 Mil.

Genscript Biotech's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-456 Mil.


Genscript Biotech Payments of Debt Historical Data

The historical data trend for Genscript Biotech's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Payments of Debt Chart

Genscript Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -148.23 -222.63 -555.41 -3.61 -192.17

Genscript Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.95 -1.67 -73.77 -118.62 -337.34

Genscript Biotech Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-456 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genscript Biotech Payments of Debt Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Payments of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Genscript Biotech Business Description

Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
Genscript Biotech Corp is a China-based provider of life science research services and products. it is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, The company estimates that over two-thirds of GenScript valuation is from its ownership stake in Legend.
Executives
Wang Luquan 2401 A concert party to an agreement to buy shares
Wang Ye 2101 Beneficial owner
Zhang Fangliang 2401 A concert party to an agreement to buy shares
Huang Lili 2202 Interest of your spouse
Hu Zhiyong 2201 Interest of corporation controlled by you
Jin Weihong 2201 Interest of corporation controlled by you
Genscript Corporation 2101 Beneficial owner
Hillhouse Fund V, L.p. 2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Gns Holdings Limited 2101 Beneficial owner
Hillhouse Capital Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager

Genscript Biotech Headlines

No Headlines